What 2020 means for the life sciences
Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.
- Pricing, patents and the PMPRB in Canada 14-12-2020
- The doctrine of equivalents in the medtech arena 18-11-2020
- The plausibility battleground at the EPO 09-11-2020
- A stricter interpretation: the EPO and antibodies 27-10-2020
- COVID-19: Protection of IP for AI tools 01-09-2020
Latest news
MSD fails in SCOTUS bid to revive record $2.5bn verdict
21-01-2021
A subsidiary of MSD has failed to revive a record $2.5bn verdict against Gilead Sciences, after the US Supreme Court refused to hear arguments that a patent was improperly invalidated.
